How Lipfendra, Inclisiran, and New Guidelines Are Changing Cholesterol Management

With more than half of U.S. adults now eligible for statins, the face of cholesterol treatment may be changing with drugs like Lipfendra and Inclisiran. FatCamera · E+/Getty A new analysis found that the twice-yearly cholesterol medication inclisiran reduced LDL cholesterol by 49% more than placebo. The FDA approved Lipfendra, the first oral PCSK9 inhibitor for adults with high LDL cholesterol. Updated cholesterol guidelines suggest more than half of U.S. adults may now be eligible for statin therapy. New medications and updated guidelines are changing how high cholesterol is treated. A systematic review and meta-analysis published in JACC: Advances on July 22 found that a new twice-yearly therapy may substantially reduce LDL cholesterol levels. The Food and Drug Administration (FDA) also approved the groundbreaking cholesterol medication Lipfendra on July 16. This new drug helped lower people’s LDL cholesterol by nearly 60%. The American Heart Association (AHA), American College of Cardiology (ACC), and several other medical organizations introduced new guidelines for the management and screening of high cholesterol earlier in 2026. Studies on the impacts of these gui…